Epidemiologic, clinical, and serologic studies generally claim a link between periodontitis and RA (Potempa et al., 2017) . This bidirectional association between RA and periodontitis can, among others, be explained by shared risk factors such as genetic predisposition, smoking, and a higher local and systemic inflammatory burden as well as by induction of autoimmunity by chronic infection with certain periodontal pathogens such as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans (Konig et al., 2016; Rosenstein, Greenwald, Kushner, & Weissmann, 2004; Wegner et al., 2010) .
In RA, ongoing research is focused on finding biomarkers for diagnosis, prognosis, treatment selection, and optimized therapy (Jog & James, 2017) . Two of the most common autoantibodies in patients with RA are rheumatoid factor (RF), directed against the Fc portion of the IgG class of antibodies, and antibodies against citrullinated proteins (ACPAs). In addition, antibodies against carbamylated proteins (anti-CarP) can precede clinical diagnosis of RA (Gan et al., 2015) . All these autoantibodies are considered to be potentially pathogenic (Derksen, Huizinga, & van der Woude, 2017) . In addition, many cytokines and chemokines are active in the joints of RA patients. These cytokines are critical in inflammation, joint damage, and RA-associated comorbidities (Brennan & McInnes, 2008) . The number of elevated cytokines and chemokines in preclinical seropositive RA, as measured in serum, predicts time to diagnosis in an age-dependent manner (Deane et al., 2010) .
Traditional approaches to control RA rely on conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS).
Advances in understanding key events in the pathogenesis of RA have led to additional biological DMARDs. When RA is clinically apparent, a number of cytokines, for example, tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1 receptor antagonist, are successfully targeted in RA treatment with biological DMARDs (Jog & James, 2017) . It is not yet well known whether treatment with biological DMARDS, besides its effect on the periodontal inflammatory burden, also results in changes in saliva and gingival crevicular fluid (GCF). For example, Äyräväinen et al., (2018) recently showed that treatment of RA with synthetic or biologic DMARDs did not affect salivary MMP-8 levels (Äyräväinen et al., 2018) .
Gingival crevicular fluid is the exudate of the periodontium that can be collected from the gingival crevice around the teeth.
Leakage of GCF out of the periodontal pocket increases when the gingival crevice becomes inflamed and reflects severity of periodontal inflammation. GCF is composed of serum and locally generated components such as tissue breakdown products, inflammatory mediators, substances from bacteria in the dental biofilm, and antibodies in response to these bacteria (Champagne et al., 2003) . Biochemical analysis of GCF offers a non-invasive means of assessing the host response in periodontal disease (Lamster, 1997) . GCF can be obtained with paper strips and crevicular washes. These methods are very technique sensitive as the quantity and quality of GCF samples are highly affected by the method of collection and analysis (Guentsch et al., 2011) .
Because of the lack of uniformity in the methodological design of studies aiming to detect which cytokines are most involved in chronic periodontitis, Tomás et al., (2017) recently developed cytokine-based predictive models to estimate the probability of presence of chronic periodontitis. Models based on a pro-inflammatory cytokine profile (granulocyte-macrophage colony-stimulating factor (GMCSF), IL-1α, IL-1β, IL-6, IL-12p40, IL-17A, IL-17F, and TNF-α) and an anti-inflammatory cytokine profile (interferon gamma [IFNγ], IL-2, IL-3, and IL-4) have a high predictive ability to distinguish patients with chronic periodontitis from periodontally healthy subjects. For example, smoking-adjusted models with an outstanding predictive accuracy showed that IL-1α, IL-1β, and IL-17A in GCF are good biomarkers for distinguishing patients with chronic periodontitis from periodontally healthy individuals. The predictive ability of these proinflammatory cytokines was further increased by incorporating antiinflammatory cytokines IFNγ and IL-10 in the GCF cytokine model.
Studies related to cytokines in GCF of RA patients can be helpful in explaining the association between periodontitis and RA.
Cytokines in RA patients with periodontitis have lastly been reviewed in 2014 (Javed et al., 2014) . The aim of this focused review was to update the current knowledge on cytokine expression in GCF of RA patients as well as to assess the effect of anti-rheumatic treatment with biological DMARDs and periodontal treatment on these cytokines.
| MATERIAL S AND ME THODS
Focused research questions for our review were as follows: (a) Which cytokines have been assessed in GCF of RA patients and what is the difference in expression of cytokines between RA patients and individuals without RA? (b) What is the influence of both RA and periodontal treatments on expression of these cytokines in GCF? MedLine/PubMed searches with different combinations of keywords "rheumatoid arthritis or RA", "crevicular fluid or GCF," "cytokines" and "treatment" until June 2019 revealed 64 articles.
Eligibility criteria were original, clinical studies, with use of statistical methods, published in English with a reference list of original and review studies. Further inclusion criteria were RA diagnosed according to the ACR 1987 or ACR 2010 revised criteria (Aletaha et al., 2010; Arnett et al., 1988) , assessment of cytokines in GCF of RA patients and systemically healthy controls (except for RA treatment studies), and description of periodontal status of the study groups.
Of the 64 potentially eligible papers, 24 papers passed the inclusion criteria (Figure 1 ). Four studies had to be excluded after in-depth analysis because no healthy control group was included.
One study had to be excluded in addition because of inconsistent or lacking data and no response of the authors on repeated request of additional data (Özçaka, Alpöz, Nalbantsoy, Karabulut, & Kabasakal, 2018) . Eight of the remaining 20 studies had been reviewed before by Javed et al., 2014. To allow for comparison of the various studies, when appropriate, only patient groups with or without chronic periodontitis and with or without RA were considered. When available, concentrations instead of amounts of cytokines were used for comparison between the study groups.
| RE SULTS

| Cytokines in GCF of RA patients
Most of the studies on biomarkers in GCF (Table 1) assessed proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A, IL-17F) and other inflammatory mediators implicated in tissue destruction in periodontitis and RA such as matrix metalloproteinases (MMPs), the pro-inflammatory mediator prostaglandin E2 (PGE 2 ), neutrophil elastase, and the receptor activator of nuclear factor-kappa B ligand (RANKL) and its inhibitor osteoprotegerin (OPG). Anti-inflammatory cytokines studied in GCF of RA patients were IL-4, IL-10, IL-18, and IL-17E. Four studies compared cytokines in GCF and serum (Cetinkaya, Guzeldemir, Ogus, & Bulut, 2013; Gümüş et al., 2013a Gümüş et al., , 2013b Silosi et al., 2015) . Some studies had overlapping study populations (Biyikoğlu et al., 2006 (Biyikoğlu et al., , 2009 Bozkurt, Berker, Akkuş, & Bulut, 2000; Bozkurt, Yetkin Ay, Berker, Tepe, & Akkuş, 2006; Gümüş et al., 2013a Gümüş et al., , 2013b ).
| Pro-inflammatory cytokines
Levels of IL-1β in GCF of RA patients and periodontitis patients were comparable, but lower than in periodontally healthy controls, however (Cetinkaya et al., 2013) . However, Miranda et al., (2007) found higher IL-1β levels in GCF of healthy controls while Biyikoğlu et al., (2006) showed IL-1β levels in GCF were comparable in periodontitis patients with or without RA. Recently, Bender et al., (2019) reported significantly higher levels of IL-1β in GCF of RA patients. Serum IL-1β was significantly lower in the RA patients than in periodontitis patients and periodontally healthy controls (Cetinkaya et al., 2013) . IL-6 levels in GCF did not differ between RA patients with periodontitis, periodontitis patients without RA, and periodontally healthy controls (Bozkurt et al., 2000) . Bozkurt et al., (2000) presumed, however, that although pockets probing depths and gingival bleeding indices in periodontally diseased individuals were higher compared to periodontally healthy controls, severity of periodontitis might have been too low to detect difference in GCF IL-6 levels. The IL-17A/E ratio was significantly higher in female RA patients than in controls (Gümüş et al., 2013b) . Miranda et al., (2007) found higher neutrophil elastase levels in GCF of periodontally matched healthy controls compared to RA patients. Biyikoğlu et al., (2006) showed that GCF levels of PGE 2 , t-PA and its inhibitor PAI-2 were comparable in periodontitis patients with or without RA, while these levels were lower in periodontally healthy controls. In another study, with overlapping study populations, Biyikoğlu et al., (2009) Full-text articles assessed for eligibility (n = 24)
| Cytokines involved in inflammation and tissue destruction
Full-text articles excluded, with reasons (n = 5):
No systemically healthy control group (4) No additional data provided (1) Studies included in qualitative synthesis (n = 19):
Cytokines in GCF of RA patients (10) Treatment of RA or periodontitis (9) TA B L E 1 Studies on cytokines in gingivocrevicular fluid (GCF) of patients with rheumatoid arthritis (RA) and systemically healthy controls (HC) with (+) or without (−) chronic periodontitis (CP) amounts of MMP-8 in GCF were lower in the healthy controls than in RA-gingivitis, RA-periodontitis, and healthy-periodontitis patients, while MMP-13 amounts did not differ between the studied groups. Moreover, patients with RA and gingivitis or periodontitis exhibited levels of MMP-8 and -13 and TIMP-1 that were similar to systemically healthy patients. GCF, but not serum, levels of MMP-9 were also found to be higher in RA patients with periodontitis compared to periodontitis patients without RA (Silosi et al., 2015) . With increasing severity of periodontal disease, increasing levels of MMP-8 levels were observed in GCF of both RA patients and persons without RA (Kirchner et al., 2017) . When the periodontal status was healthy, no differences in MMP-8 levels were found between RA patients and controls, but in case of periodontitis, MMP-8 levels in GCF of RA patients with periodontitis were higher. In addition, Kirchner et al., (2017) in their treatment study (Table 3) showed that TNF-α, RANKL, and OPG were higher in GCF and serum of patients with periodontitis, irrespective of their RA status, than in healthy controls.
| Anti-inflammatory cytokines
Concentration of IL-4 and IL-10 in GCF of RA patients and periodontitis patients was comparable, but lower than in periodontally healthy controls (Bozkurt et al., 2006; Cetinkaya et al., 2013) . Serum IL-10 was comparable between RA patients, periodontitis patients, and periodontally healthy controls (Cetinkaya et al., 2013) . The IL-17A/E ratio was significantly higher in female RA patients than in controls (Gümüş et al., 2013b) .
| Effect of treatment
| Periodontal condition in RA patients
Overall, RA patients have significantly less teeth and a worse periodontal condition than controls with or without chronic periodontitis (Bender et al., 2019; Biyikoğlu et al., 2006 Biyikoğlu et al., , 2009 Bozkurt et al., 2006; Cetinkaya et al., 2013; Gümüş et al., 2013a Gümüş et al., , 2013b Kirchner et al., 2017) , but some studies reported no obvious differences in periodontal condition between RA patients and controls (Bozkurt et al., 2000; Miranda et al., 2007) . 
| Anti-rheumatic treatment with biological DMARDs
With regard to anti-rheumatic treatment and their effect on the composition of GCF, only the effect of anti-TNF-α treatment on cytokine levels has been reported ( (Armitage, 2000) .
GCF TNF-α levels significantly decreased after starting anti-TNF-α therapy compared to pretreatment levels (Kadkhoda et al., 2016) as well as to GCF TNF-α levels in RA patients not receiving anti-TNF-α therapy (Mayer et al., 2009 (Mayer et al., , 2013 . In addition, compared to pretreatment, GCF IL-1β and IL-8 levels had decreased significantly after 4 weeks of anti-TNF-α therapy in RA patients with periodontitis (Üstün et al., 2013) . Furthermore, anti-TNF-α therapy led to significant improvement in periodontal indices of inflammation, independent of oral hygiene status of the patients (Kadkhoda et al., 2016; Mayer et al., 2013; Üstün et al., 2013) as well as that RA disease activity decreased significantly in RA patients with and without chronic periodontitis (Üstün et al., 2013) . The other studies (Kadkhoda et al., 2016; Mayer et al., 2009 Mayer et al., , 2013 did not report whether RA disease activity changed. In summary, anti-TNF-α treatment in RA patients apparently lowers levels of pro-inflammatory cytokines in GCF (TNF-α, IL-1β, and IL-8), which, besides the beneficial effect on RA, may result in decreased inflammation of the periodontium.
| Periodontal treatment
Five studies assessed the influence of periodontal treatment on biomarkers in GCF of RA patients (Table 3) Pre-versus post-treatment: significantly higher BOP and GI post-treatment (10 with CP, 6 without CP)
Pre-versus post-treatment: significantly lower Il−1β, Il−8 post-treatment no PD, BOP, CAL, GI, PI Armitage 1999 RA + versus RA-: CAL, BOP, GI significantly higher in RA+ RA + versus RA-: TNF-α amount (no concentration assessed) significantly higher in RA-(2017) also showed that periodontal therapy resulted in a decrease of GCF vitamin D levels in RA patients, while again no changes of vitamin D levels were found in serum. GCF and serum RANKL/OPG ratios did not change either. Furthermore, periodontal treatment in RA patients with periodontitis did not result in a significant decrease of IL-1β, MMP-8, and IL-10 levels (Cosgarea et al., 2019) . Kurgan et al., (2016) reported that MMP-8 levels decreased significantly in GCF in patients with or without RA after non-surgical periodontal treatment, whereas for IL-6 and PGE2 GCF levels a significant decrease was observed only in RA patients. In a follow-up study, Kurgan et al., (2017) additionally assessed main components of the plasminogen activating system (t-PA and PAI-2). They showed that t-PA in GCF significantly decreased in RA patients after periodontal therapy. Its inhibitor PAI-2 did not change significantly, however. Thus, non-surgical periodontal therapy in RA patients seems to have limited effects on the local action of the plasminogen activating system. Abbreviations: Armitage 1999 (Armitage, 2000 ; BOP: bleeding on probing; CAL: clinical attachment level; DAS28: disease activity score 28 joint count; DMARDs: disease-modifying anti-rheumatic drugs; GI: gingivitis index; HC + CP: healthy controls with CP; IL: interleukin; MMP: matrix metalloproteinase; MTX: methotrexate; n.a.: not assessed; NSAIDs: non-steroidal anti-inflammatory drugs; OPG: osteoprotegerin; PAI-2: plasminogen activator inhibitor-2; PD: periodontal pocket depth; PGE 2 : prostaglandin E 2 ; PI: plaque index; RA + CP: RA patients with chronic periodontitis (CP); RANKL; receptor activator of nuclear factor-kappa β ligand; TNF-α: tumor necrosis factor-α; t-PA: tissue/blood vessel-type plasminogen activator.
In summary, periodontal treatment results in a local anti-inflammatory effect as the pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and mediators implicated in tissue destruction (MMP-8, PGE2) decrease in GCF, but not in serum. This effect seems to be more pronounced in RA patients with periodontitis than in periodontitis patients without RA. Together with the reported improvement of RA disease activity, RA patients can benefit from periodontal treatment.
| D ISCUSS I ON
Overall, RA patients have increased GCF and serum levels of pro-inflammatory cytokines and proteins, despite anti-rheumatic treatment. Presence of periodontitis increases these levels. The interaction of RA and periodontitis is also reflected in the effect of treatment. Anti-TNF-α therapy decreases pro-inflammatory cytokines in GCF especially when RA and periodontitis coexist.
Besides the beneficial effect on RA, anti-TNF-α therapy also lowers clinical periodontal inflammation. Although it has been shown that RA treatment lowers levels of pro-inflammatory cytokines in GCF, clinical periodontal inflammation does not return levels in healthy subjects without chronic periodontitis. This is in line with a recent study of Ziebolz et al., (2018) Smit et al., 2012) .
For the same reason, treatment of one disease may impact the other disease.
Methodological concerns related to the collection and analysis of GCF are important factors that need to be considered when studying GCF (Lamster & Ahlo, 2007) . Contradictory results could be due to the lack of uniformity in the methodological design of the studies. For example, quantity and quality of GCF samples are highly affected by the method of collection and analysis. GCF collection with filter paper strips is used in most studies and is the method of choice for most biomarkers in immunologic studies (Guentsch et al., 2011) . Standardized collection of GCF is almost impossible in observational studies, as different patient groups are investigated and ideal sampling conditions to avoid contamination of GCF samples with blood are mostly absent (patients with good oral hygiene and low gingival inflammation). As a result, contradictory data may be obtained, underlining the lack of understanding of the complexity of the association between periodontitis and RA .
Although it is hypothesized that inflamed mucosal surfaces are likely initiation sites for RA, the most common RA-associated autoantibodies, that is, RF and ACPAs, have not yet been studied in GCF of RA patients. Up to now, only Harvey et al., (2013) reported on ACPAs in GCF of periodontally inflamed sites in individuals without RA. Activity of human and bacterial citrullinating enzymes (PAD and PPAD), however, has been studied in GCF of RA patients. The enzyme activity was clearly associated with periodontitis but to a lesser extent with RA and the presence of P. gingivalis (Laugisch et al., 2016) . Regarding expression of inflammatory proteins in GCF, a specific role for certain periodontal pathogens was not found (Kirchner et al., 2017; Laugisch et al., 2016) .
Keeping in mind the methodological concerns related to collection and analysis of GCF, this focused review points toward a bidirectional relationship between periodontitis and RA, which is probably caused by non-specific inflammatory burden. RA patients could benefit from periodontal screening, as periodontal treatment in RA patients lowers local periodontal inflammatory burden and improves RA disease activity scores. Data for a more specific relationship are barely present in GCF. To determine potential causality between periodontitis and RA, presence and production of RA-associated antibodies in the periodontium should be investigated, preferably with assessment of the microbial composition of the dental biofilm. In this respect, Eriksson et al., (2019) very recently showed that most RA patients with moderate or severe periodontitis were seropositive for ACPA (86%) as well as that these patients had a subgingival microbial profile that differed from RA patients with no or mild periodontitis and had higher levels of oral and systemic inflammatory mediators.
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